Epigenomic Priming as an Immunotherapy Enhancer in Ovarian Cancer

Project: Research project

Project Details


we propose two translational objectives embedded in the clinical trial: Aim 1: Measure the antigen burden induced by treatment with guadecitabine in human tumors in relationship to clinical response. Aim 2: Determine the anti-tumor activity of CD8+ effector T cells induced by treatment with guadecitabine and pembrolizumab in relationship to clinical response. We will take advantage of the unique resource provided by the ready-to-activate investigator initiated phase II clinical trial testing the combination of pembrolizumab and guadecitabine (SGI-110) in women with platinum resistant OC and measure tumor antigen expression and immune activation in tumor biopsies obtained before and after treatment.
Effective start/end date5/1/174/30/21


  • U.S. Army Medical Research and Materiel Command (W81XWH-17-1-0141 P00002)


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.